An ongoing clinical trial will determine whether the addition of weekly nab-paclitaxel to gemcitabine or carboplatin improves PFS versus the gemcitabine-carboplatin doublet as first-line therapy for patients with metastatic TNBC.
Denise A. Yardley, MD
An ongoing clinical trial will determine whether the addition of weekly nab-paclitaxel to gemcitabine or carboplatin improves progression-free survival (PFS) versus the gemcitabine-carboplatin doublet as first-line therapy for patients with triple-negative metastatic breast cancer (TNMBC).
Still in the patient-accrual stage, the phase II/III trial will involve a cumulative total of almost 800 patients with untreated TNMBC,Denise A. Yardley, MD, a medical oncologist at Sarah Cannon Research Institute in Nashville, Tennessee, and colleagues reported in a poster presentation at the San Antonio Breast Cancer Symposium (SABCS) 2014.
During the phase II portion of the study, investigators will enroll 240 patients, who will be randomized to nab-paclitaxel 125 mg/m2plus gemcitabine 1000 mg/m2or carboplatin AUC 2 or to the gemcitabine-carboplatin doublet. The primary objectives are to evaluate the safety and efficacy of the nab-paclitaxel regimens and to identify the nab-paclitaxel doublet to carry forward into the phase III trial. The primary endpoint of phase II is investigator-assessed PFS.
The phase III investigation will compare the nab-paclitaxel regimen chosen from phase II with the gemcitabine-carboplatin doublet in 550 patients. The primary endpoint is PFS as assessed by independent radiology review.
Eligible patients have pathologically confirmed triple-negative breast cancer at screening and measurable disease and estrogen and progesterone receptor expression <1%, and are HER2 negative as defined by immunohistochemistry (IHC) 0 or +1, fluorescent in situ hybridization (FISH) negative, or IHC+2 and FISH negative. Patients must have received adjuvant or neoadjuvant anthracycline therapy (unless ruled out by treating physician) or an alternative adjuvant/neoadjuvant regimen, but they must not have undergone prior therapy for metastatic disease.
“Biomarker analyses may advance the current understanding of triple-negative breast cancer biology and response to treatment,” Yardley and colleagues noted in their SABCS poster presentation. “This study may identify a nab-paclitaxelbased cytotoxic chemotherapy combination as a new first-line standard treatment regimen for triple negative metastatic breast cancer.”
According to a representative for study sponsor Celgene, the phase II component of the trial should be completed during 2015 in time for reporting by the end of the year.
<<<
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More